Pexidartinib
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tenosynovial Giant Cell Tumor
Conditions
Tenosynovial Giant Cell Tumor
Trial Timeline
Mar 15, 2021 → May 31, 2026
NCT ID
NCT04703322About Pexidartinib
Pexidartinib is a phase 2 stage product being developed by Daiichi Sankyo for Tenosynovial Giant Cell Tumor. The current trial status is active. This product is registered under clinical trial identifier NCT04703322. Target conditions include Tenosynovial Giant Cell Tumor.
What happened to similar drugs?
1 of 2 similar drugs in Tenosynovial Giant Cell Tumor were approved
Approved (1) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04703322 | Phase 2 | Active |
| NCT04526704 | Approved | Completed |
| NCT04488822 | Phase 3 | Active |
| NCT04223635 | Phase 1 | Completed |
| NCT02734433 | Phase 1 | Completed |
Competing Products
2 competing products in Tenosynovial Giant Cell Tumor
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pexidartinib | Daiichi Sankyo | Phase 3 | 44 |
| Pexidartinib | Daiichi Sankyo | Approved | 43 |